• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Latest News

Seeking Sustainable Solutions: Can Passion and Profit Coexist in Pharma ESG Efforts?
Seeking Sustainable Solutions: Can Passion and Profit Coexist in Pharma ESG Efforts?

October 15th 2024

Industry leaders gather to discuss different ways life sciences organizations can champion their environmentally-conscious younger employees while combatting still-entrenched public mistrust.

Exelixis, Merck Strike Deal to Develop Zanzalintinib for Multiple Types of Cancer
Exelixis, Merck Strike Deal to Develop Zanzalintinib for Multiple Types of Cancer

October 15th 2024

Pharma’s Cold Calling: CGT Space at a Critical Crossroads
Pharma’s Cold Calling: CGT Space at a Critical Crossroads

October 15th 2024

FDA Approves Single-Dose Regimen of UCB’s Bimzelx for Moderate-to-Severe Plaque Psoriasis, Active Psoriatic Arthritis
FDA Approves Single-Dose Regimen of UCB’s Bimzelx for Moderate-to-Severe Plaque Psoriasis, Active Psoriatic Arthritis

October 15th 2024

Pharmaceutical Executive: September 2024 Issue (PDF)

Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.

 Click the title above for a link to open the Pharmaceutical Executive July/August 2024 issue in an interactive PDF format.

Conference Coverage

View All
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma

June 4th 2024

Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection
Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection

June 4th 2024

Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer
Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer

June 3rd 2024

Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status
Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status

June 3rd 2024

Latest Videos
Podcasts

All News